Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb 1;51(2):69-76.
doi: 10.2165/11596650-000000000-00000.

Role of modelling and simulation: a European regulatory perspective

Affiliations
Review

Role of modelling and simulation: a European regulatory perspective

Siv Jönsson et al. Clin Pharmacokinet. .

Abstract

Modelling and simulation (M&S) of clinical data, e.g. pharmacokinetic, pharmacodynamic and clinical endpoints, is a useful approach for more efficient interpretation of collected data and for extrapolation of knowledge to the entire target population. This type of documentation is included in the majority of marketing authorization applications for new medicinal products. This article summarizes the current status of regulatory review with respect to the role of M&S in Europe from the perspective of the Swedish Medical Products Agency. At present, regulatory bodies in Europe encourage the application of the M&S approach during drug development. However, there is a lack of consensus and transparent guidance documents. The main regulatory usage is in the evaluation of dose choices in sub-populations and as support for the dosing regimen in general. The regulatory review of conestat alfa illustrates how the dose recommendation was revised during the approval procedure based on M&S information. A survey of marketing authorization applications for new medicinal products approved in 2010 revealed that the use of the information gained from M&S documentation varies with respect to both regulatory review and the applicants' presentation of the data in the submitted dossier. Increased utilization and broadened application of M&S is anticipated in pharmaceutical development, where one area of focus is medicines for paediatric patients. Accordingly, the regulatory agencies will need to increase their capability to assess and utilize this type of information, and an interactive process among regulatory agencies is warranted to provide more unified regulatory assessment and guidance. Moreover, applicants are encouraged to expand on the usage of exposure-response models to map the systemic exposure range that yields safe and efficacious treatment and to improve the presentation of the gained knowledge in summary documents of the marketing authorization applications.

PubMed Disclaimer

Similar articles

Cited by

References

    1. AAPS J. 2005 Oct 07;7(3):E544-59 - PubMed
    1. J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):185-97 - PubMed
    1. Eur J Drug Metab Pharmacokinet. 2000 Jan-Mar;25(1):49-58 - PubMed
    1. J Clin Pharmacol. 2010 Sep;50(9 Suppl):20S-30S - PubMed
    1. Br J Clin Pharmacol. 2007 Sep;64(3):266-77 - PubMed

LinkOut - more resources